Publication:
SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?

dc.contributor.authorGuisad-Hernandez, Paloma
dc.contributor.authorBlanco-Lobo, Pilar
dc.contributor.authorVillaoslada, Isabel
dc.contributor.authorde-Felipe, Beatriz
dc.contributor.authorLucena, Jose M
dc.contributor.authorMartin-Gutierrez, Guillermo
dc.contributor.authorCastro, María Jose
dc.contributor.authorGutierrez-Valencia, Alicia
dc.contributor.authorSanchez-Codez, Maria Isabel
dc.contributor.authorGaboli, Mirella
dc.contributor.authorNeth, Olaf
dc.contributor.authorOlbrich, Peter
dc.date.accessioned2023-02-09T11:40:18Z
dc.date.available2023-02-09T11:40:18Z
dc.date.issued2021-06-09
dc.description.abstractRecently, 94 inborn errors of immunity (IEI) patients suffering from COVID-19 have been described, overall demonstrating a mild phenotype [1] although more severe disease manifestations have been suggested for patients with alterations in the interferon (IFN) signaling pathway, including auto-antibodies against type I IFN [2]. Patients with STAT1 GOF mutations show a complex and often severe phenotype, combining an increased susceptibility of fungal, (myco-) bacterial and viral infections as well as autoimmune and autoinflammatory manifestations [3]. Characteristically, in response to type I and type II IFN stimulation, these patients show STAT1 hyperphosphorylation [3, 4]. Whether in the context of SARS-CoV-2 infection, the hyperactivation of the IFN-JAK1/2-STAT1 pathway would be protective (antiviral effect) or deleterious (hyperinflammation) is unclear. Ruxolitinib (a selective JAK1/2 inhibitor) has been successfully used in STAT1 GOF patients controlling many disease manifestations [5] and also resulted in improved pulmonary function and faster recovery from lymphopenia in previously healthy individuals suffering from severe COVID-19
dc.description.versionSi
dc.identifier.citationGuisado Hernández P, Blanco Lobo P, Villaoslada I, de Felipe B, Lucena JM, Martín Gutierrez G, et al. SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance? J Clin Immunol. 2021 Oct;41(7):1502-1506.
dc.identifier.doi10.1007/s10875-021-01081-9
dc.identifier.essn1573-2592
dc.identifier.pmcPMC8189704
dc.identifier.pmid34109505
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189704/pdf
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007/s10875-021-01081-9.pdf
dc.identifier.urihttp://hdl.handle.net/10668/17982
dc.issue.number7
dc.journal.titleJournal of clinical immunology
dc.journal.titleabbreviationJ Clin Immunol
dc.language.isoen
dc.organizationHospital Universitario Puerta del Mar
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number1502-1506
dc.provenanceRealizada la curación de contenido 10/07/2025.
dc.publisherSpringer New York LLC
dc.pubmedtypeCase Reports
dc.pubmedtypeLetter
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.relation.publisherversionhttps://doi.org/10.1007/s10875-021-01081-9
dc.rights.accessRightsRestricted Access
dc.subjectCOVID-19
dc.subjectInterferon-Stimulated Gene Factor 3
dc.subjectPyrazoles
dc.subjectCOVID-19 Drug Treatment
dc.subject.decsCOVID-19
dc.subject.decsMutación
dc.subject.decsSARS-CoV-2
dc.subject.decsLinfopenia
dc.subject.decsVirosis
dc.subject.decsInterferones
dc.subject.decsInsuficiencia multiorgánica
dc.subject.decsAntineoplásicos inmunológicos
dc.subject.decsDiabetes mellitus tipo 2
dc.subject.meshChild
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshJanus Kinases
dc.subject.meshMutation
dc.subject.meshNitriles
dc.subject.meshPyrimidines
dc.subject.meshSARS-CoV-2
dc.subject.meshSeverity of Illness Index
dc.titleSARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?
dc.typeletter to the editor
dc.type.hasVersionVoR
dc.volume.number41
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format